Munich-based antibody-drug conjugate developer Tubulis has secured a rapid oral presentation slot at the American Society of Clinical Oncology Annual Meeting in Chicago for its lead oncology asset TUB-040, a NaPi2b-targeting ADC under evaluation in the ongoing Phase I/IIa NAPISTAR 1-01 trial (NCT06303505). The presentation, scheduled for 30 May 2026, will feature updated and maturing dose escalation data from the ovarian cancer cohort of the trial, building on interim results that generated significant attention at the European Society for Medical Oncology Congress in October 2025.
The ASCO appearance arrives at a moment of considerable momentum for Tubulis and, more broadly, for the NaPi2b target class after years of clinical disappointment. The significance of the data set being presented cannot be understood without that context.
Why does the NaPi2b target carry such a complicated clinical history in ovarian cancer?
NaPi2b, a sodium-dependent phosphate transporter highly expressed in ovarian serous carcinoma, has long been considered a theoretically attractive ADC target. The antigen is broadly present across the relevant tumour type, lacks meaningful expression in most healthy tissue, and its biology allows for receptor-mediated internalisation, a prerequisite for effective ADC payload delivery. Yet the clinical track record prior to TUB-040 was one of repeated failure. Two earlier NaPi2b-targeted ADCs, lifastuzumab vedotin and upifitamab rilsodotin, demonstrated feasibility but limited efficacy in clinical trials, resulting in the discontinuation of their development. Upifitamab rilsodotin showed a modest objective response rate of approximately 34% in early-phase studies, but in the pivotal Phase II UPLIFT trial it failed to meet its primary endpoint, achieving an objective response rate of just 15.6%, with additional safety concerns including severe bleeding prompting regulatory attention. Roche and Zymeworks also abandoned NaPi2b programmes without advancing them to substantive trials. The consistent pattern of early promise followed by clinical underperformance created legitimate scepticism about whether the target itself was viable, or whether the failures reflected limitations of the conjugation platforms and payloads chosen by those earlier developers.
TUB-040’s ESMO 2025 data directly challenged that scepticism. The distinction lies in the engineering. The molecule is built on Tubulis’ proprietary Tubutecan technology, which employs cysteine-selective conjugation chemistry through an ethynylphosphonamidate P5 linker to attach the topoisomerase I inhibitor exatecan to an Fc-silenced IgG1 antibody targeting NaPi2b, achieving a homogeneous drug-to-antibody ratio of 8. The P5 chemistry is designed to produce a highly stable, hydrophilic ADC that resists premature linker cleavage in systemic circulation while enabling efficient payload release within the tumour microenvironment. That technical architecture directly addresses the two failure modes that undermined earlier NaPi2b programmes: insufficient tumour exposure at tolerable systemic doses, and off-target toxicity from linker instability.
What did the ESMO 2025 interim readout establish, and what questions remain open going into ASCO?
In the proof-of-concept dose escalation study, responses were observed at all doses above 1.67 mg/kg, including a complete response at the 2.5 mg/kg dose. At dose levels from 1.67 mg/kg to 3.3 mg/kg, the objective response rate was 59% and the disease control rate was 96%. The confirmed objective response rate was 50%, with 93% of responses ongoing at the data cut-off. The patient population was heavily pretreated, with a median of four prior lines of therapy, and the analysis included patients who had previously received mirvetuximab soravtansine. Responses occurred early, beginning at treatment cycle two, deepened over time, and were also observed in patients who had received mirvetuximab soravtansine as their most recent line of therapy. On the safety side, the tolerability profile was notably clean for a topoisomerase I inhibitor-based ADC. No clinically relevant bleeding, pneumonitis, ocular toxicity, stomatitis, or neuropathy were reported, distinguishing TUB-040 from other agents in the class, and there were no fatal treatment-emergent adverse events and no discontinuations due to adverse events across the 1.67 to 3.3 mg/kg cohort range.
Those figures are striking for a Phase I population in this setting, but they require careful interpretation. The ESMO data reflected 46 patients within the active dose range and 67 patients across all cohorts. The numbers are small by the standards that will eventually govern regulatory submissions. Response rates in dose escalation studies, particularly those without biomarker selection, routinely compress in larger confirmatory trials, and the absence of a pre-specified primary efficacy endpoint in Phase I limits how directly these figures translate to pivotal design assumptions. The ASCO 2026 presentation is specifically described as covering maturing data from the ongoing dose escalation component of the ovarian cancer cohort. The clinical and regulatory community will be examining whether response durability has been sustained as follow-up extends, whether dose-response relationships across the 1.67 to 5.3 mg/kg range have been fully characterised, and whether the safety profile remains intact as patient numbers grow and longer-term toxicity patterns emerge.
How does the ASCO 2026 slot change Tubulis’ development trajectory and what pivotal readout pressure does it create?
Rapid oral acceptance at ASCO in the gynaecological oncology programme is a meaningful validation signal. It reflects the abstract review committee’s assessment that the data are clinically significant and warrant broad professional attention, an assessment that carries weight in a specialty where abstract selection is highly competitive. For Tubulis, the timing is important. The company closed a Series C financing round valued at approximately 308 million euros shortly before the ESMO presentation, a round described as targeting the acceleration of TUB-040’s clinical development. The ASCO slot effectively extends the data narrative into 2026 with a fresh readout, reinforcing investor confidence and, more practically, informing the design parameters for a pivotal programme that has already been signalled as a near-term priority.
Tubulis has indicated plans to initiate pivotal trials with TUB-040, explore earlier lines of treatment in ovarian cancer, and expand into combination regimens and new solid tumour indications. That is a broad agenda, and the sequencing decisions being made now will define the regulatory timeline. The most immediate strategic question is whether to advance TUB-040 into a registrational trial in third- or fourth-line platinum-resistant ovarian cancer as a monotherapy, pursue earlier-line positioning where the competitive landscape is less crowded but the comparator bar is higher, or prioritise combination studies that could expand commercial potential but complicate trial design. The FDA fast track designation for platinum-resistant ovarian cancer, granted in mid-2024, provides some regulatory flexibility but does not accelerate the trials themselves.
What does TUB-040’s safety architecture tell oncologists about its real-world adoption potential, and what uncertainties persist?
The toxicity profile reported to date deserves specific attention because it addresses a persistent concern with topoisomerase I inhibitor-based ADCs as a class. Agents such as trastuzumab deruxtecan, while demonstrating strong efficacy across multiple tumour types, carry established risks of interstitial lung disease and pneumonitis that require active monitoring protocols and have periodically led to fatal outcomes in post-marketing settings. TUB-040’s absence of clinically relevant pulmonary, ocular, or haematological toxicity in the NAPISTAR 1-01 data is consistent with the theoretical advantages of the P5 linker’s hydrophilicity and stability, which are expected to reduce bystander payload release and off-target tissue exposure. If that profile holds across larger patient numbers, it would represent a genuinely meaningful differentiation point for prescribers and health technology assessment bodies evaluating reimbursement.
The caveat is that Phase I safety data, collected in a structured dose escalation design with rigorous monitoring and a relatively short median exposure period, frequently presents a more favourable picture than real-world use. The study reported a 35% rate of grade 3 or higher treatment-emergent adverse events, with the maximum tolerated dose identified at 4.4 mg/kg. That figure warrants monitoring as the programme advances, particularly if the recommended Phase II dose is set at or above the 3.3 mg/kg upper range of the primary efficacy cohort. The commercial dose will need to balance tumour exposure, tolerability, and manufacturability. Each of those parameters introduces uncertainty that Phase I data cannot fully resolve. Long-term tolerability, cumulative dose effects, and pharmacokinetic variability across broader patient populations are questions that the maturing ASCO dataset may begin to address but will not definitively settle.
What does the ASCO 2026 readout mean for the competitive positioning of NaPi2b as a validated oncology target?
The broader implication of the NAPISTAR 1-01 programme, if the ASCO data continue to support earlier findings, is a rehabilitation of NaPi2b as a viable ADC target after a period of sustained clinical failure. That matters beyond Tubulis. If TUB-040 advances into a registrational programme with a compelling efficacy and safety data package, it will likely reactivate industry interest in NaPi2b from development-stage biotechs and potential licensing partners. The target’s overexpression profile extends into lung adenocarcinoma and endometrial cancer, and the NAPISTAR 1-01 trial is simultaneously evaluating TUB-040 in a non-small cell lung cancer cohort, data from which have not yet been presented. A positive NSCLC readout would materially expand the commercial addressable market and could reframe TUB-040 from a gynaecological oncology asset into a broader platform play.
The competitive pressure on Tubulis comes less from other NaPi2b developers at this stage, given the failures of predecessor programmes, and more from the crowded broader ADC landscape in ovarian cancer. Mirvetuximab soravtansine, which targets folate receptor alpha, is already approved for platinum-resistant ovarian cancer in folate receptor-high patients and is establishing treatment pathway precedent. Sacituzumab govitecan and trastuzumab deruxtecan are generating data in the same indication from different target angles. The clinical community evaluating TUB-040’s ASCO data will be asking whether the response rates, durability, and safety profile observed in a biomarker-unselected population justify displacing or complementing existing options, and whether a future biomarker-selection strategy could sharpen the benefit-risk profile further. Those are the questions ASCO 2026 will need to advance, even if it cannot yet fully answer them.
ASCO 2026: Tubulis set to present maturing Phase I/IIa data on TUB-040 exatecan ADC in PROC added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →